Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN · Real-Time Price · USD
4.310
+0.110 (2.62%)
At close: Sep 5, 2025, 4:00 PM
4.120
-0.190 (-4.41%)
After-hours: Sep 5, 2025, 5:55 PM EDT
Lantern Pharma Employees
Lantern Pharma had 24 employees as of December 31, 2024. The number of employees increased by 3 or 14.29% compared to the previous year.
Employees
24
Change (1Y)
3
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
-$802,029
Market Cap
46.55M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 24 | 3 | 14.29% |
| Dec 31, 2023 | 21 | -2 | -8.70% |
| Dec 31, 2022 | 23 | 7 | 43.75% |
| Dec 31, 2021 | 16 | 1 | 6.67% |
| Dec 31, 2020 | 15 | 8 | 114.29% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LTRN News
- 2 days ago - Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial - Business Wire
- 23 days ago - Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates - Business Wire
- 4 weeks ago - Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial - Business Wire
- 4 weeks ago - Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™ - Business Wire
- 5 weeks ago - Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300 - Business Wire
- 5 weeks ago - Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors - Business Wire
- 6 weeks ago - Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial - Business Wire
- 6 weeks ago - Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy - Business Wire